• What we do

    Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

     

     

  • Our investors

    OSI is a £600M fund investing in the most exciting start-ups built on world-leading Oxford science.

     

    www.oxfordsciencesinnovation.com